Innovectis collaborates with the venture capital fund “CARMA FUND I CAPITAL”. CARMA FUND is an early-stage investment fund for advancing Life Science and Healthcare technologies. It supports Life Science projects and young start-ups. The fund started off with a First Closing in June 2022 and has €50M under management. Investors include Goethe University of Frankfurt am Main, Ascenion GmbH, the company Evotec and the European Investment Fund.
In a collaboration with the pharmaceutical companies BMS and Evotec, beLAB2122 is funding translational drug discovery and early development projects, to implement first-in-class therapeutic options for various indications. The beLAB2122 consortium has a total of $ 20 million available for projects with Goethe University and other academic partners from the Rhine-Main-Neckar region.